Bristol Myers Squibb: The Rerating Was Fast - The Proof Will Be Slow (Rating Downgrade)

Core Insights - The article discusses Bristol Myers Squibb (BMY) and highlights concerns regarding the Eliquis patent cliff, legacy erosion, and execution risks, which were significant factors when the stock was near 5-year lows in October 2025 [1]. Company Analysis - Bristol Myers Squibb is facing challenges related to the expiration of the Eliquis patent, which could impact revenue streams significantly [1]. - The company has been under scrutiny for its legacy products and the potential erosion of market share as competition increases [1]. - Execution risks are noted as a critical factor that could affect the company's operational performance and overall market position [1]. Investment Perspective - The article emphasizes the importance of evaluating valuations and dividend offerings as part of the investment analysis for Bristol Myers Squibb [1]. - The author suggests that despite the challenges, there may be potential investment opportunities if the company can navigate these risks effectively [1].